BROOKS

Brooks Laboratories Limited

Pharmaceutical formulations including tablets, capsules and liquids

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

brookslabs.net(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹67.57
Market cap
199 Cr
Stock P/E
15.1
P/B
1.62
ROE (FY26)
20.0%
ROCE (FY26)
19.6%
Operating margin (FY26)
6.4%
Debt / equity (FY26)
0.06
OCF / EBITDA (FY26)
131.6%
OCF / EBITDA (3Y)
14.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Brooks Laboratories is a pharmaceutical company that makes medicines at Baddi in Himachal Pradesh and sells them to domestic and export customers, and it holds a 49% stake in the Brooks Steriscience joint venture.

Company snapshot

105thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 28.7% — the business keeps a healthy share of every rupee it earns.
Concerns
  • ✗Only 14% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales24 Cr22 Cr18 Cr18 Cr21 Cr21 Cr23 Cr26 Cr23 Cr17 Cr20 Cr23 Cr
Operating expenses (approx.)23 Cr21 Cr17 Cr18 Cr19 Cr19 Cr22 Cr22 Cr21 Cr16 Cr20 Cr21 Cr
EBITDA2 Cr1 Cr0.38 Cr0.28 Cr2 Cr2 Cr2 Cr3 Cr3 Cr0.73 Cr0.68 Cr2 Cr
OPM %7.1%5.0%2.1%1.6%7.3%7.7%6.6%12.3%10.8%4.4%3.4%8.1%
Other income0.09 Cr0.15 Cr0.65 Cr0.07 Cr0.20 Cr0.03 Cr0.62 Cr0.22 Cr0.39 Cr0.13 Cr0.44 Cr0.18 Cr
Interest0.19 Cr0.21 Cr0.27 Cr0.16 Cr0.32 Cr0.28 Cr0.26 Cr0.30 Cr0.28 Cr0.16 Cr0.09 Cr0.21 Cr
Depreciation0.44 Cr0.43 Cr0.46 Cr0.40 Cr0.43 Cr0.38 Cr0.39 Cr0.39 Cr0.39 Cr0.39 Cr0.41 Cr0.42 Cr
Profit before tax-2 Cr-4 Cr-10 Cr-2 Cr-4 Cr-2 Cr-1 Cr10 Cr8 Cr5 Cr2 Cr-2 Cr
Tax %0.0%-0.7%0.0%0.0%0.0%0.0%-13.7%0.0%0.0%0.0%0.0%0.0%
Net profit-2 Cr-4 Cr-10 Cr-2 Cr-4 Cr-2 Cr-1 Cr10 Cr8 Cr5 Cr2 Cr-2 Cr
EPS (₹)₹-0.64₹-1.51₹-3.77₹-0.94₹-1.51₹-0.82₹-0.54₹3.25₹2.71₹1.87₹0.52₹-0.61

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales77 Cr91 Cr63 Cr79 Cr83 Cr86 CrSign in free for the trailing twelve months
Operating expenses (approx.)77 Cr105 Cr90 Cr76 Cr78 Cr79 CrSign in free for the trailing twelve months
EBITDA0.52 Cr-14 Cr-26 Cr3 Cr5 Cr7 CrSign in free for the trailing twelve months
OPM %0.7%-15.8%-41.8%4.0%6.0%8.2%Sign in free for the trailing twelve months
Other income0.74 Cr0.91 Cr0.20 Cr0.96 Cr0.88 Cr1 CrSign in free for the trailing twelve months
Interest3 Cr3 Cr2 Cr0.84 Cr1 Cr0.84 CrSign in free for the trailing twelve months
Depreciation7 Cr7 Cr7 Cr2 Cr2 Cr2 CrSign in free for the trailing twelve months
Profit before tax-9 Cr-24 Cr-39 Cr2 Cr-10 Cr25 CrSign in free for the trailing twelve months
Tax %-115.4%19.2%18.7%1.7%-1.8%0.0%Sign in free for the trailing twelve months
Net profit-19 Cr-19 Cr-32 Cr-20 Cr-10 Cr25 CrSign in free for the trailing twelve months
EPS (₹)₹6.31₹-7.82₹-12.57₹-7.67₹-3.72₹8.35Sign in free for the trailing twelve months
Dividend payout %—————0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital25 Cr25 Cr25 Cr26 Cr29 Cr29 Cr
Reserves54 Cr38 Cr49 Cr39 Cr69 Cr93 Cr
Borrowings31 Cr24 Cr6 Cr5 Cr6 Cr7 Cr
Other liabilities52 Cr37 Cr30 Cr20 Cr20 Cr18 Cr
Total liabilities162 Cr196 Cr110 Cr90 Cr124 Cr148 Cr
Fixed assets (net)107 Cr108 Cr14 Cr13 Cr13 Cr13 Cr
CWIP0.68 Cr15 Cr0 Cr0 Cr1 Cr1 Cr
Investments0.02 Cr0.06 Cr64 Cr43 Cr74 Cr92 Cr
Loans & advances0.44 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Inventories24 Cr28 Cr11 Cr10 Cr9 Cr11 Cr
Trade receivables14 Cr18 Cr13 Cr16 Cr20 Cr16 Cr
Cash & bank0.88 Cr3 Cr0.02 Cr0.13 Cr0.04 Cr7 Cr
Other assets16 Cr25 Cr7 Cr8 Cr7 Cr8 Cr
Total assets162 Cr196 Cr110 Cr90 Cr124 Cr148 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity4 Cr-37 Cr-14 Cr-10 Cr3 Cr9 Cr
Cash from investing-5 Cr-25 Cr0.49 Cr0.18 Cr-46 Cr-3 Cr
Cash from financing1 Cr64 Cr11 Cr10 Cr43 Cr0.17 Cr
Net cash flow0.49 Cr2 Cr-3 Cr0.10 Cr-0.08 Cr7 Cr
Free cash flow (OCF − Capex)-1 Cr-65 Cr-15 Cr-10 Cr2 Cr6 Cr

Ratios

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %-5.3%-13.1%-46.4%3.4%-8.4%19.6%
ROE %-24.5%-12.1%-43.0%-29.9%-10.2%20.0%
Debtor days657173758868
Inventory days18415999787181
Days payable24116220512610584
Cash conversion cycle768-32275465
OCF / EBITDA %n.m.——-300.9%51.0%131.6%
OCF / EBITDA % (3 years)—————14.0%
Debt / equity0.390.380.080.080.060.06
Current ratio0.751.250.841.351.481.72
Net debt / EBITDA58.10——1.531.220.10